BERGENBIO ANNOUNCES UPDATE FROM INVESTIGATIONAL PHASE II TRIALS ASSESSING BEMCENTINIB IN HOSPITALISED COVID-19 PATIENTS
· Day 29 follow-up of last patient enrolled has now occurred in BGBC020 and ACCORD2_002 · Data receipt is ongoing and evaluation of efficacy data is underway · Exploratory analyses are looking to define subsets of patients with baseline markers indicative of increased disease severity with the potential for greater benefit · Bemcentinib was well tolerated throughout both studies, in the ACCORD2 study there was a numerically lower number of deaths up to day 29 in the bemcentinib arm (1 of 28 with bemcentinib + standard of care vs 5 of 32 in patients treated with standard of care